You may not have realized it, but making medicines is a dirty job.

A pair of new reports highlights the point: One finds troubling pollution emanating from plants in India that supply more than two dozen drug makers around the world, while the other underscores a failure by numerous antibiotic makers to disclosure discharges into the environment.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe that US-FDA can inspect for compliance with the cGMPs (Current Good Manufacturing Practices) which are US federal regulations. They get enough push back about ‘where is that in the regulations’ without adding environmental issues. Those are covered in the US (or nowadays, perhaps not) by the US EPA. I am not aware of the EPS working to ever do foreign inspections but I may be wrong – that does happen often.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy